Qureight Secures $8.5 Million Funding to Revolutionise Medical Research

Qureight, a Cambridge-based health tech company pioneering digital infrastructure for complex medical data, has secured a substantial $8.5 million in funding. This investment, led by Hargreave Hale AIM VCT, signifies a significant step forward for the company's ambitious mission to revolutionise treatment options for heart and lung diseases.

‍

Founded with the aim of addressing the challenges faced by patients with complex heart and lung conditions, Qureight recognises the inefficiencies in current medical research processes. Dr. Muhunthan Thillai, Qureight's founder and CEO, highlights the arduous task researchers face in manually extracting crucial information from vast amounts of data, a process both time-consuming and costly.

‍

To combat this, Qureight has developed an AI-powered platform that collaborates with NHS partnerships to streamline the collection and structuring of medical data in real-time. By automating these processes, Qureight aims to expedite the analysis of data, ultimately accelerating drug discovery and improving patient outcomes.

‍

Dr. Thillai emphasizes the significance of this funding round in advancing Qureight's mission. With the support of esteemed investors such as Hargreave Hale AIM VCT, XTX Ventures, and Guinness Ventures, Qureight is poised to expand its AI-driven product portfolio and venture into new disease areas, including lung cancer.

‍

The potential of Qureight's technology extends beyond addressing the challenges of heart and lung diseases. By leveraging clinical trial imaging analysis and data curation, Qureight aims to unlock insights that could lead to the development of novel treatments across a range of medical conditions.

‍

Central to Qureight's approach is its commitment to collaboration. Strategic partnerships with leading pharmaceutical companies like AstraZeneca and Vicore Pharma underscore Qureight's dedication to driving innovation in the healthcare industry.

‍

One of the key innovations offered by Qureight's platform is the ability to create virtual trial patients. This groundbreaking approach not only promises to make clinical trials more cost-effective but also holds the potential to enhance diversity within trials, ensuring that treatments are effective across diverse demographics.

‍

Looking ahead, Qureight is focused on expanding its global reach and diversifying its data sources. Partnerships with institutions like the King Faisal Hospital in Saudi Arabia underscore Qureight's commitment to harnessing diverse datasets to drive meaningful insights.

‍

The close of Qureight's Series A funding round marks a significant milestone in the company's journey. With a robust foundation in place and a clear vision for the future, Qureight is poised to continue making strides in transforming the landscape of medical research and improving patient care.